



Review Article

## Management Of Female Stress Urinary Incontinence: Contemporary Review of Conservative and Surgical Strategies

Dr. Abhinav. B<sup>1</sup>, Dr. Nithesh Jain<sup>2</sup>, Dr. Nitish R Jayaharan<sup>3</sup>

<sup>1</sup>M. Ch Urology, DrNB (Urology), Junior Consultant, Apollo Hospital, Chennai.

<sup>2</sup>M. Ch Urology, Senior Consultant and Clinical Lead, Department of Urology Apollo Hospital, Chennai.

<sup>3</sup>MBBS, Junior Resident, Department of Urology Apollo Hospital, Chennai.

 OPEN ACCESS

### ABSTRACT

#### Corresponding Author:

**Dr. Abhinav. B**  
M.Ch Urology, DrNB (Urology)  
Email:  
[abhinavbalaji15@gmail.com](mailto:abhinavbalaji15@gmail.com)

*Received:* 02-07-2025  
*Accepted:* 05-08-2025  
*Published:* 30-08-2025

Stress urinary incontinence (SUI) is one of the most common pelvic floor disorders affecting women and is characterized by involuntary leakage of urine during physical exertion, coughing, sneezing, or activities that increase intra-abdominal pressure. It significantly impairs physical comfort, sexual health, emotional well-being, and social functioning [1,7]. The prevalence rises with age, parity, obesity, menopause, and connective tissue weakening [1,7]. Contemporary management emphasizes conservative treatment as the initial therapeutic approach, particularly in mild-to-moderate disease and in women wishing to avoid surgery [3,4]. Pelvic floor muscle training (PFMT) remains the most evidence-based first-line intervention, with demonstrated improvements in symptom severity, pad use, and quality of life [3,4]. Adjunctive options including biofeedback, electrical stimulation, magnetic stimulation, vaginal devices, pessaries, and structured lifestyle modification may improve outcomes in selected patients [4,10]. Emerging therapies such as vaginal laser treatment, radiofrequency remodeling, platelet-rich plasma, and stem-cell-based interventions have generated interest, although long-term evidence remains limited [18,19]. Surgical treatment, including mid-urethral slings, autologous fascial slings, colposuspension, bulking agents, and artificial urinary sphincters, is reserved for women with persistent symptoms after failed conservative management or severe anatomical dysfunction [5,6,15]. This review summarizes current understanding of pathophysiology, available treatment modalities, comparative effectiveness, evolving technologies, and future directions in personalized management of female SUI.

Copyright© International Journal of  
Medical and Pharmaceutical Research

**Keywords:** stress urinary incontinence, women, pelvic floor muscle training, biofeedback, sling surgery, conservative management, urinary incontinence.

### INTRODUCTION

Urinary incontinence is a common and distressing condition affecting millions of women globally. It is defined as any involuntary leakage of urine and is associated with substantial physical, psychological, and economic burden [1,7]. Among the recognized subtypes, stress urinary incontinence (SUI) is the most prevalent in younger and middle-aged women. It refers to involuntary urine loss during effort, exertion, coughing, sneezing, laughing, or exercise in the absence of detrusor contraction [2]. Urge urinary incontinence is characterized by leakage associated with urgency, while mixed urinary incontinence combines features of both stress and urgency-related symptoms [2].

Population studies estimate that up to 50% of adult women experience some degree of urinary incontinence during their lifetime, with SUI accounting for a significant proportion of these cases [1,7]. Risk factors include vaginal childbirth, pelvic floor trauma, obesity, chronic cough, menopause, prior pelvic surgery, and connective tissue weakness [1,7]. Despite its prevalence, many women delay seeking treatment due to embarrassment or the misconception that leakage is a normal consequence of aging.

Modern treatment strategies recommend conservative management as first-line therapy because it is safe, cost-effective, and non-invasive [3,4,16]. Surgical intervention is generally considered only when structured conservative therapy fails or when severe anatomical dysfunction is present [15,16].

## **PATHOPHYSIOLOGY OF STRESS URINARY INCONTINENCE**

Female continence depends on coordinated interaction between urethral sphincter competence, pelvic floor support structures, connective tissue integrity, neural control, and pressure transmission mechanisms [1,2]. SUI develops when urethral closing pressure becomes insufficient to resist increases in bladder pressure during stress events.

One major mechanism is **urethral hypermobility**, resulting from weakening of the endopelvic fascia, pubourethral ligaments, and levator ani support. This leads to downward movement of the bladder neck and proximal urethra during coughing or exertion, impairing pressure transmission [1,2].

A second mechanism is **intrinsic sphincter deficiency (ISD)**, in which the urethral sphincter loses coaptation strength due to aging, denervation, prior surgery, radiation, or estrogen deficiency [15,16].

Additional contributors include hypoestrogenism after menopause, obesity-related chronic pressure loading, recurrent childbirth trauma, and neurological dysfunction [1,7]. Most women exhibit a combination of support failure and sphincter weakness rather than a single isolated mechanism.

## **CONSERVATIVE MANAGEMENT**

### **Pelvic Floor Muscle Training**

Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is the cornerstone of conservative treatment [3,4]. It involves repeated voluntary contraction of the levator ani and periurethral muscles to improve urethral support and reflex closure during sudden rises in intra-abdominal pressure.

Typical supervised regimens include repeated contractions held for 6–10 seconds, followed by relaxation, performed in multiple sets daily over at least 3 months [3]. Structured programs supervised by physiotherapists are superior to unsupervised instruction.

Systematic reviews have shown that women undergoing PFMT are significantly more likely to report cure or improvement than those receiving no treatment. Reported improvement rates range from 50% to over 70%, depending on symptom severity, adherence, and supervision [3,4].

### **Biofeedback**

Biofeedback provides visual or auditory cues during pelvic floor contraction using pressure sensors or electromyography. It helps patients identify the correct muscles and optimize exercise performance [4].

This modality is particularly useful in women unable to voluntarily contract the pelvic floor or those who plateau with conventional PFMT. Evidence suggests that biofeedback combined with PFMT may offer additional benefit compared with exercises alone [4].

### **Electrical Stimulation**

Electrical stimulation activates pelvic floor muscles and pudendal nerve pathways through vaginal or surface electrodes. Low-frequency impulses provoke passive contractions and may enhance neuromuscular recruitment [10].

It is especially useful in women with profound weakness or inability to initiate contractions. Several trials demonstrate reduction in leakage episodes and symptom scores [10].

### **Magnetic Stimulation**

Extracorporeal magnetic stimulation uses pulsed magnetic fields to induce pelvic floor contractions while the patient sits fully clothed on a treatment chair. Because it is non-invasive and painless, patient acceptance is often high [4].

Short-term studies report symptomatic improvement, but evidence remains less robust than PFMT-based therapy [4].

### **Vaginal Devices and Pessaries**

Mechanical support devices may be valuable in selected women. Continence pessaries elevate the bladder neck and compress the urethra, reducing leakage during activity [9]. They are especially useful in women with pelvic organ prolapse, pregnancy, elderly patients unfit for surgery, or those needing temporary symptom control.

Vaginal cones provide weighted resistance training and may improve muscle awareness and strength, although long-term adherence is variable [4].

### **Lifestyle and Behavioral Measures**

Lifestyle modification forms an essential component of treatment. Weight reduction in overweight women significantly reduces leakage frequency [8]. Smoking cessation may reduce chronic cough-related stress episodes. Management of constipation decreases repetitive straining. Timed voiding and bladder training may improve associated urgency symptoms [11].

These low-risk interventions should accompany all other therapies.

## **EMERGING NON-SURGICAL THERAPIES**

### **Vaginal Laser Therapy**

Er:YAG and fractional CO<sub>2</sub> laser systems aim to stimulate collagen remodeling, mucosal tightening, angiogenesis, and tissue rejuvenation in the anterior vaginal wall. Proposed benefits include improved suburethral support and continence improvement [18].

Some early studies demonstrate symptom score reduction; however, randomized evidence remains inconsistent [18].

### **Radiofrequency Therapy**

Radiofrequency devices deliver controlled thermal energy to submucosal tissues, promoting collagen contraction and neocollagenesis. Preliminary studies suggest modest improvement in mild SUI [19].

### **Regenerative Medicine**

Platelet-rich plasma (PRP), stem cell injections, and tissue engineering approaches aim to restore sphincter bulk and neuromuscular function. Early pilot studies are promising, particularly in intrinsic sphincter deficiency, but these therapies remain investigational [19].

## **PHARMACOTHERAPY**

Unlike urgency incontinence, there is no universally established oral medication for female SUI. Duloxetine has shown improvement in urethral sphincter activity and symptom reduction but is often limited by nausea and poor tolerability [17]. Topical vaginal estrogen may benefit postmenopausal women with coexisting urogenital atrophy [16].

## **SURGICAL MANAGEMENT**

Surgery is considered when conservative treatment has failed after adequate duration, symptoms remain bothersome, or severe urethral dysfunction exists [15,16].

### **Mid-Urethral Slings**

Mid-urethral sling procedures remain the most commonly performed surgery worldwide. Long-term cure rates commonly exceed 80% in appropriately selected patients [5,13,15].

### **Burch Colposuspension**

Burch colposuspension suspends periurethral tissues to Cooper's ligament and remains an effective non-mesh surgical option [6].

### **Autologous Fascial Sling**

This is useful in recurrent SUI or intrinsic sphincter deficiency, particularly when synthetic mesh is contraindicated [15].

### **Urethral Bulking Agents**

Injectable agents increase urethral coaptation and are suitable for frail patients or those preferring minimally invasive therapy [20].

### **Artificial Urinary Sphincter**

Reserved for severe refractory cases after multiple failed procedures [15].

## **COMPARATIVE EFFECTIVENESS**

Current evidence consistently supports PFMT as the most effective first-line conservative intervention [3,4]. Supervised PFMT outperforms unsupervised exercise. Combination approaches involving PFMT with biofeedback or electrical stimulation may yield superior short-term outcomes in selected patients [4,10].

Surgical treatment generally provides greater absolute cure rates than conservative therapy but involves procedural risks such as voiding dysfunction, pain, mesh complications, or recurrence [5,6,12].

## **SPECIAL POPULATIONS**

### **Postpartum Women**

Pregnancy and vaginal delivery are major risk factors for pelvic floor injury. Early postpartum PFMT reduces later incontinence risk and improves recovery [3].

### **Athletes**

High-impact sports increase intra-abdominal pressure and are associated with higher SUI prevalence. Pelvic floor rehabilitation is beneficial [4].

### **Elderly Women**

Frailty, mobility limitations, and polypharmacy influence treatment choice. Conservative therapy and pessaries are often preferable initially [16].

## LIMITATIONS OF CURRENT EVIDENCE

Despite extensive literature, several limitations remain. Many studies use heterogeneous definitions of cure, varying pad tests, and different PFMT protocols. Long-term durability data for emerging technologies are sparse. Sham-controlled studies for laser and radiofrequency treatment remain limited [18,19].

## FUTURE DIRECTIONS

Future management is likely to become increasingly individualized. Smartphone-guided exercise adherence programs, wearable biofeedback devices, and home digital therapeutics may improve long-term compliance. Biomarker-based phenotyping may help distinguish support failure from sphincter deficiency and guide therapy selection. Regenerative medicine may eventually offer restorative rather than compensatory treatment [19].

## CONCLUSION

Female stress urinary incontinence remains a highly prevalent and treatable condition with major quality-of-life implications. Conservative therapy should remain the initial management strategy for most women [3,4,16]. Among available modalities, pelvic floor muscle training continues to be the most strongly evidence-supported treatment and should be offered in a supervised, structured manner whenever possible [3]. Adjunctive measures such as biofeedback, electrical stimulation, pessaries, and lifestyle optimization can further enhance outcomes in selected patients [4,10]. Emerging non-invasive technologies including laser, radiofrequency, and regenerative therapies are promising but currently lack sufficient long-term evidence for universal recommendation [18,19]. Surgical intervention remains highly effective for persistent or severe cases after failed conservative treatment [5,15]. A patient-centered, stepwise, and individualized treatment pathway offers the best opportunity for durable continence restoration and improved quality of life.

## REFERENCES

1. Abrams P, Cardozo L, Wagg A, Wein A, editors. *Incontinence*. 6th ed. Bristol: International Continence Society; 2017.
2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association/International Continence Society joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn*. 2010;29(1):4-20.
3. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment for urinary incontinence in women: a Cochrane systematic review. *Cochrane Database Syst Rev*. 2018;10:CD005654.
4. Dumoulin C, Adewuyi T, Booth J, Bradley C, Burgio K, Hagen S, et al. Adult conservative management. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. *Incontinence*. 6th ed. Bristol: ICS; 2017. p. 1443-1628.
5. Ford AA, Rogerson L, Cody JD, Ogah J. Mid-urethral sling operations for stress urinary incontinence in women. *Cochrane Database Syst Rev*. 2017;7:CD006375.
6. Imamura M, Hudson J, Wallace SA, MacLennan G, Shimonovich M, Omar MI, et al. Surgical interventions for women with stress urinary incontinence: systematic review and network meta-analysis. *BMJ*. 2019;365:11842.
7. Milsom I, Altman D, Lapitan MC, Nelson R, Sillén U, Thom D. Epidemiology of urinary incontinence. In: Abrams P, Cardozo L, Houry S, Wein A, editors. *Incontinence*. Paris: Health Publication Ltd; 2013. p. 15-108.
8. Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. *N Engl J Med*. 2009;360(5):481-90.
9. Hagen S, Stark D. Conservative prevention and management of pelvic organ prolapse in women. *Cochrane Database Syst Rev*. 2011;(12):CD003882.
10. Berghmans B, Hendriks E, Bernards A, de Bie R, Omar MI. Electrical stimulation with non-implanted electrodes for urinary incontinence in women. *Cochrane Database Syst Rev*. 2013;(6):CD012390.
11. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. *Cochrane Database Syst Rev*. 2004;(1):CD001308
12. Labrie J, Berghmans B, Fischer K, Milani AL, van der Wijk I, Smalbraak DJ, et al. Surgery versus physiotherapy for stress urinary incontinence. *N Engl J Med*. 2013;369(12):1124-33.
13. Serati M, Ghezzi F, Cattoni E, Braga A, Siesto G, Cromi A, et al. Tension-free vaginal tape for the treatment of urodynamically stress incontinence: efficacy and adverse effects at 10-year follow-up. *Eur Urol*. 2012;61(5):939-46.
14. Chapple CR, Cruz F, Deffieux X, Milani R, Arlandis S, Artibani W, et al. Consensus statement of the European Urology Association on urinary incontinence management. *Eur Urol*. 2022;81(1):49-62.
15. Kobashi KC, Albo ME, Dmochowski RR, Ginsberg DA, Goldman HB, Gomelsky A, et al. Surgical treatment of female stress urinary incontinence: AUA/SUFU guideline. *J Urol*. 2017;198(4):875-83.
16. Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. *Eur Urol*. 2018;73(4):596-609.
17. Osman NI, Esperto F, Chapple CR. Duloxetine in the treatment of stress urinary incontinence. *Ther Adv Urol*. 2018;10(11):327-36.
18. Gaspar A, Brandi H. Non-ablative vaginal Er:YAG laser for stress urinary incontinence: prospective clinical outcomes. *Lasers Surg Med*. 2017;49(3):273-80.
19. Leone Roberti Maggiore U, Finazzi Agrò E, Soligo M, et al. Radiofrequency treatment for female stress urinary incontinence: systematic review. *Int Urogynecol J*. 2021;32(6):1417-26.
20. Juma S, Brito CG. Transurethral bulking agents for female stress urinary incontinence. *Curr Urol Rep*. 2017;18(12):96.